Allarity Therapeutics has established a facility in Horsholm, Northern Europe, and the FDA requires CLIA certification for biomarker testing.
2 reports, 1 independent
Updated Oct 30
No new developments lately
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Allarity Therapeutics has established a facility in Horsholm, Northern Europe, and the FDA requires CLIA certification for biomarker testing.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Allarity Therapeutics secured CLIA certification for its Hørsholm lab.1 source
Allarity Therapeutics sets up facility in Northern Europe; FDA mandates CLIA certification for biomarker testing.1 source
Keep exploring
The entities involved
- FDA
-
Northern Europe
northern region of the European continent
Nothing else this week.
Related events
- Both the FDA and the European Medicines Agency govern drug approval processes.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- FDA rated generic equivalent to brand Climara Pro.
- Arthur Caplan questioned the FDA regarding the status of clinical trials in 2006.